Prof. Roberto Crea is the founder and CEO of Protelica, Inc., a protein engineering company he established in 2006 after the sale of his Bioren, Inc. to Pfizer. A pioneer in biotechnology, Roberto Crea was one of the first 5 employees and the first Nucleic Acids Director at Genentech in 1977, where he established the DNA synthesis department and dramatically improved the use of synthetic DNA to gene synthesis. Dr. Crea is the sole inventor of the first two US Patents issued to Genentech in 1979 and 1982 His laboratory was instrumental to produce numerous bio-therapeutics, including Human Insulin, Human Growth Hormone, Interferons and numerous MAbs. His entrepreneurial career, starting in 1982, includes the founding of several biotech start-ups, including Creative BioMolecules in 1982, Creagen in 1999, BioRen and CreAgri Inc. in 2000, Agroils in 2005 and Protelica in 2006. He was also Neurex’ CSO and SVP from 1994 to 1997, after he merged his company, Creagen, and prior to the acquisition of Neurex, Inc. by Elan Pharmaceuticals. In 2005, Dr. Crea sold BioRen, Inc. to Pfizer, retained the rights to use the DNA mutagenesis technology for any proteins outside the IgG class and started Protelica, Inc. Dr. Crea holds a Ph.D. in Biochemistry from the University of Pavia, Italy and the title of Professor in Molecular Genetics from University of Messina (IT). Dr. Crea has authored more than 40 US Patents and has received numerous scientific awards.
Prof. Giuseppe Nisticò Scientific Advisory Board-Protelica
Giuseppe Nisticò is Full Professor of Pharmacology since 1980. He has a Degree in Medicine with honors (1965) and a specialization in Neuropsychiatry (1968). He was Director of the Institute of Pharmacology, University of Messina (1976-1983) and then Director of the Institute of Pharmacology, Faculty of Medicine, University of Catanzaro. From 1990 to 2011 he was Full Professor of Pharmacology, University of Rome, Tor Vergata. From 1995 to 1998 he was President of the Calabria Region and from 1999 to 2004 was Member of the European Parliament and President of a Committee of the Italian Government for a network of excellence in Biomedicine and Biotechnology. From 2006 to 2011 he was Director of the Pharmaceutical Biotechnologies Center and of the European School for the Assessment of New Medicines (University of Rome Tor Vergata). In addition, from 2008 to 2011 he was President of the Scientific Committee for the New Degree Course in Pharmacy. From 2011 till now he is responsible for the International Relations of the same Degree Course in Pharmacy. From 2010 to 2011 he was Commissioner of the European Brain Research Institute (EBRI) Fondazione “Rita Levi-Montalcini”. Since 2011 he is General Director of EBRI. He was member of the Committee for Human Medicinal Products of the European Medicines Agency (EMA) from 2004 to 2010 and since 2007 he is member of the EMA Management Board. Author of approx 300 publications in international journals of Pharmacology and Neuroscience and in addition he is author or editor of more than 25 volumes published by international Publishing Companies. His main scientific interests: role of neurotransmitters in sleep/arousal mechanisms and pharmacological modulation of synaptic plasticity.
Prof. AihuiPan Chairman of the Board. Sinobioway Ltd. (China)
Professor at Peking University, Senior Researcher at Beijing Institute of Market Economy. In 1984, Dr. Pan graduated from Hunan Medical College with a Bachelor Degree of Medicine. In 1989, Dr. Pan graduated from Chinese Institute of Space Medico-Engineering with a Master Degree of Aerospace Medicine. In 1991, Dr. Pan received a doctor degree in Biochemistry from Biology Department of Peking University. Dr. Pan is the former Deputy Director of Biotechnology Department of Peking University (1993-1996) and former President of Peking University Shenzhen Alumni Association (1998-2003). Currently he serves as the Chairman of the Board of Sinobioway Group Co., Ltd. and China Bioeconomy Group Co., Ltd. Other key positions that Dr. Pan holds include: Senior Consultant of China Medicinal Biotech Association, Member of the Standing Committee of Chinese Society of Biotechnology, Deputy Director of Industry Promotion Association of Chinese Society of Biotechnology, Vice Executive Chairman of the Investment and Financing Services Committee of CCOIC (China Chamber of International Commerce), project evaluation expert of national "863" program in the field of biology, evaluation expert of “National Biological Industry Base” of NDRC (National Development and Reform Commission), member of the feasibility study committee of national major science and technology project “Prevention and Control of AIDS, Viral Hepatitis and Other Major Infectious Diseases”, project evaluation expert of national major science and technology project “Major New Drug Discovery”, member of "National Industrial Development Strategy" research group, expert committee member of China Development Bank, member of the first Scientific Advisory Board of Shenzhen Municipal People's Government, and chief expert of national “863” Program’s key project “Study on the Large-scale Preparation of Nucleic Acid and Peptide Drugs”. In 1995, when Dr. Pan was studying for his second doctoral degree in political economics at Peking University, he first put forward the concept of “bioeconomy”, built the theoretical system of bioeconomy and established a brand new thought system and ten innovative theories. Dr. Pan is the proposer of bioeconomy concept, the creator of bioeconomic theory, the founder of the bioeconomic model, and the builder of bioeconomic system. For his outstanding contributions in academic research, in the development of the mode combining enterprises, universities and research institutes, and in the development of biological high-tech industries, Dr. Pan is the recipient of numerous honors and awards: the title of "Advanced Worker" from State Science and Technology Commission (1992), Outstanding Contribution Award in developing high-tech industries from Peking University (1993), Scientific and Technological Progress Award from State Education Commission (1994), “the world’s 500 most influential leaders” by American Celebrity Association (1997), Chinese Outstanding Youth Science and Technology Entrepreneurship Award and Peking University Science and Technology Industry Outstanding Contribution Award(1998), “China’s Top 10 Outstanding Talents of the Century” by Ministry of Science and Technology(1999), Shenzhen Pengnian Science and Technology Award (2000), “China’s Top 10 Dream Team of Managers in 2000” (2000),”Top 10 Young Promising Entrepreneurs”(rank first) by New Economics (2001), ”Top 10 Most Valuable Managers” by Talents Magazine (2001), “Top 10 Chinese Economic Elites” (2005), and “60 Men of 60 Years” Award from Chinese medicine industry.